



Medications for Weight Loss in Adults

B.C. Provincial Academic Detailing (PAD) Service

March 2024

Overview

1. Health Canada. Drug and Health Product Portal. <https://dhpp.hpfb-dgpsa.ca/>
2. US Food & Drug Administration. FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. US Food & Drug Administration.
 - US Food & Drug Administration. Guidance for Industry: Developing Products for Weight Management. 2007. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-products-weight-management-revision-1>
 - US Food & Drug Administration. Wegovy Review. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm;
 - US Food & Drug Administration. Saxenda Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm
 - US Food & Drug Administration. Contrave Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000TOC.cfm
 - US Food & Drug Administration. Xenical Review. 1998. https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020766a.cfm
 - US Food & Drug Administration. GLP1 agonists pulmonary aspiration. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
 - US Food & Drug Administration. GLP1 agonists alopecia. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
 - US Food & Drug Administration. GLP1 agonists suicidal thoughts actions. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
 - US Food & Drug Administration. GLP1 agonists suicidal thoughts actions. Jan 2024. <https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type>
4. European Medicines Agency.
 - European Medicines Agency. Clinical evaluation of medicinal products used in weight control. 2016. <https://www.ema.europa.eu/en/clinical-evaluation-medicinal-products-used-weight-control-scientific-guideline>
 - European Medicines Agency. Wegovy Review. 2022. <https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy>
 - European Medicines Agency. Saxenda Review. 2015. <https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda>
 - European Medicines Agency. Mysimba Review. 2015. <https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba>
 - European Medicines Agency. GLP1 agonists pulmonary aspiration. Sep 2023. <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-25-28-september-2023>
 - European Medicines Agency. GLP1 agonists suicidal thoughts actions. Jul 2023. <https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists>
 - European Medicines Agency. Naltrexone-bupropion cardiovascular. Sep 2023. <https://www.ema.europa.eu/en/medicines/human/referrals/mysimba>
5. Health Canada.
 - Health Canada. GLP1 agonists suicide, self-harm, suicidal ideation. Nov 2023. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/new.html>
6. Wharton S et al. Diabetes Obes Metab 2022;24:94-105
7. Wharton S et al. Postgrad Med 2022;134:14-19
8. Muller T et al. Nat Rev Drug Disc 2022;21:201-223
9. Lean M et al. Int J Obes 2014;38:689-97
10. Patel H et al. Diabetes Obes Metab 2023;26:473-81
11. Agarwal A et al. JAMA 2024; epub Feb 19

Weight loss outcomes: snapshot

1. SURMOUNT-1. N Engl J Med 2022;387:205-16
2. STEP 1. N Engl J Med 2021;384:989-1002
3. SCALE. N Engl J Med 2015;373:11-22

4. COR-1. Lancet 2010;376:595-605
5. Obesity Canada, International Obesity Collaborative Consensus Statement. Nov 2023. <https://obesitycanada.ca/oc-news/consensus-statement-body-mass-index-bmi/>
6. SURMOUNT-2. Lancet 2023;402:613-26.
7. STEP 2. Lancet 2021;397:971-84
8. SCALE diabetes. JAMA 2015;314:687-99

Weight loss outcomes: details

1. Shi Q et al. Lancet 2022;399:259-69
2. SURMOUNT-1. N Engl J Med 2022;387:205-16
3. US Food & Drug Administration.
 - US Food & Drug Administration. Wegovy Review. 2021. [https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm;);
 - US Food & Drug Administration. Saxenda Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm
 - US Food & Drug Administration. Contrave Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000TOC.cfm
 - US Food & Drug Administration. Xenical Review. 1998. https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/020766a.cfm
4. European Medicines Agency.
 - European Medicines Agency. Wegovy Review. 2022. <https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy>
 - European Medicines Agency. Saxenda Review. 2015. <https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda>
 - European Medicines Agency. Mysimba Review. 2015. <https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba>
5. STEP 1. N Engl J Med 2021;384:989-1002
6. SCALE. N Engl J Med 2015;373:11-22
7. COR-1. Lancet 2010;376:595-605
8. US Food & Drug Administration. Guidance for Industry: Developing Products for Weight Management. 2007. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/developing-products-weight-management-revision-1>
9. European Medicines Agency. Clinical evaluation of medicinal products used in weight control. 2016. <https://www.ema.europa.eu/en/clinical-evaluation-medicinal-products-used-weight-control-scientific-guideline>
10. Padwal R et al. Int J Obes 2007;10:1567-70

Cardiovascular outcomes

1. SELECT 2023. N Engl J Med. 2023;389:2221-32
2. STEP HFpEF 2023. N Engl J Med. 2023;389:1069-84
3. US Food & Drug Administration. Guidance for Industry: Treatment for Heart Failure. 2019. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/treatment-heart-failure-endpoints-drug-development-guidance-industry>
4. US Food & Drug Administration. Qualification of the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and its Component Scores. 2020. <https://www.fda.gov/drugs/clinical-outcome-assessment-coa-qualification-program/ddt-coa-000084-kansas-city-cardiomyopathy-questionnaire-kccq>
5. Spertus J et al. J Am Coll Cardiol 2020;76:2379-90

Dosing, timing of effect, dose response

1. Health Canada. Drug and Health Product Portal. <https://dhpp.hpfb-dgpsa.ca/>
2. US Food & Drug Administration. FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. SURMOUNT-1. N Engl J Med 2022;387:205-16
4. SURMOUNT-4. JAMA 2024;331:38-48
5. STEP 1. N Engl J Med 2021;384:989-1002
6. STEP 1 extension. Diabetes Obes Metab 2022;24:1553-64
7. STEP 2. Lancet 2021;397:971-84
8. STEP 4. JAMA 2021;14:1414-25
9. STEP 6. Lancet Diabetes Endocrinol 2022;10:193-206
10. SELECT 2023. N Engl J Med. 2023;389:2221-32
11. SCALE. N Engl J Med 2015;373:11-22
12. SCALE adolescents N Engl J Med 2020;382:2117-28
13. SCALE diabetes. JAMA 2015;314:687-99
14. COR-1. Lancet 2010;376:595-605
11. US Food & Drug Administration.

- US Food & Drug Administration. Wegovy Review. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm;
 - US Food & Drug Administration. Saxenda Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm
 - US Food & Drug Administration. Contrave Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000TOC.cfm
15. McKesson Canada. PharmaClik. <https://pharmaclik-login.mckesson.ca/>
16. Wharton S et al. Postgrad Med 2022;134:14-19

Clinical Consideration: tirzepatide, semaglutide, liraglutide

1. Health Canada. Drug and Health Product Portal. <https://dhpp.hpfb-dgpsa.ca/>
2. US Food & Drug Administration. FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. SELECT 2023. N Engl J Med. 2023;389:2221-32
4. Wharton S et al. Diabetes Obes Metab 2022;24:94-105
5. Wharton S et al. Postgrad Med 2022;134:14-19
6. American Society of Anesthesiologists. 2023. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>
7. ISMP Canada Safety Bulletin. Vol. 23: Issue 9; Sept 27, 2023.
8. Jones P et al. Can J Anaesth 2023;70:1281-86
9. Obesity Canada. Canadian Adult Obesity Clinical Practice Guidelines: Pharmacotherapy for Obesity Management. 2020. <https://obesitycanada.ca/guidelines/pharmacotherapy>
10. Liyun H et al JAMA Int Med 2022;182:513-519
11. Diabetes Canada 2018. Clinical Practice Guidelines for the prevention and management of diabetes in Canada: Pharmacologic glycemic management of type 2 diabetes in adults: 2020. <https://guidelines.diabetes.ca/cpg/chapter-13-2020-update>
12. Lean M et al. Int J Obes 2014; 38:689-97
13. Ahren B et al. Diabetes Obes Metab.2018;20:2210–2219.
14. Sodhi M et al. JAMA 2023; 330;18:1795-97
15. STEP 1. N Engl J Med 2021;384:989-1002
16. STEP 2. Lancet 2021;397:971-84
17. SCALE Diabetes. JAMA 2015;314:687-99
18. Health Canada. GLP1 agonists suicide, self-harm, suicidal ideation. Nov 2023. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/new.html>
19. European Medicines Agency. Oct 2023. GLP1 agonists thyroid cancer. <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-october-2023>
20. European Medicines Agency. GLP1 agonists pulmonary aspiration. Sep 2023. <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-25-28-september-2023>
21. European Medicines Agency. GLP1 agonists suicidal thoughts actions. Jul 2023. <https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists>
22. European Medicines Agency. Naltrexone-bupropion cardiovascular. Sep 2023. <https://www.ema.europa.eu/en/medicines/human/referrals/mysimba>
23. US Food & Drug Administration. GLP1 agonists pulmonary aspiration. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
24. US Food & Drug Administration. GLP1 agonists alopecia. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
25. US Food & Drug Administration. GLP1 agonists suicidal thoughts actions. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
26. US Food & Drug Administration. GLP1 agonists suicidal thoughts actions. Jan 2024. <https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type>
27. Yang Y et al. Diabetes Obes Metab 2023;1-9
28. SURMOUNT-1. N Engl J Med 2022;387:205-16
29. SURMOUNT-2. Lancet 2023;402:613-26.
30. Lin F et al. 2023 PLOS ONE 2023;18:e0285197
31. Patel H et al. Diabetes Obes Metab 2024;26:473-81
32. US Food & Drug Administration. Wegovy Review. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000TOC.cfm;
33. US Food & Drug Administration. Saxenda Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206321Orig1s000TOC.cfm
34. Skelley J et al. J Amer Pharm Assoc 2024;64:204-11
35. US Food and Drug Administration, Guidance for Industry Pregnancy, Lactation, Reproductive Potential: Labelling for Human Prescription Drug and Biological Products <https://www.fda.gov/media/90160/download>

Clinical considerations: naltrexone-bupropion

1. Health Canada. Drug and Health Product Portal. <https://dhpp.hpfb-dgpsa.ca/>
2. US Food & Drug Administration. FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. US Food & Drug Administration. Contrave Review. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/200063Orig1s000TOC.cfm
4. LIGHT 2014 <https://clinicaltrials.gov/study/NCT01764386>
5. CONVENE 2016 <https://clinicaltrials.gov/study/NCT02638129>
6. Onakpoya I et al. BJCP 2019;86:646-67
7. Canada's Drug and Health Technology Agency. Contrave Review. 2020. <https://www.cadth.ca/naltrexone-hydrochloride-and-bupropion-hydrochloride>
8. Ninh A et al. A A Case Report 2017;9:224-26
9. Shehebar M. J Pain. 2016;4:S83
10. Pi-Sunyer X et al. International Journal of Obesity. 2019;43:2085-2094
11. Nissen S et al. JAMA 2016;315:990-1004
12. European Medicines Agency. Naltrexone-bupropion cardiovascular. Sep 2023. <https://www.ema.europa.eu/en/medicines/human/referrals/mysimba>
13. US Food and Drug Administration. Guidance for Industry. 2020. Pharmacokinetics in Patients with Impaired Renal Function. <https://www.regulations.gov/document/FDA-2010-D-0133-0021>
14. US Food and Drug Administration. Guidance for Industry. 2003. Pharmacokinetics in Patients with Impaired Hepatic Function. <https://www.fda.gov/media/71311/download>
15. BC Provincial Academic Detailing Service. Antidepressants for Major Depressive Disorder: Drug Information to Support Drug Therapy Decisions. 2020. <https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/antidepressant-drug-information-newsletter.pdf>

Drug interactions

1. Health Canada Drug Product Database. <https://dhpp.hpfb-dgpsa.ca/dhpp/search?query=contrave>
2. US Food & Drug Administration. FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>
3. Indiana University Cytochrome P450 Drug Interaction Table <https://drug-interactions.medicine.iu.edu/MainTable.aspx>
4. Lexicomp Drug Interactions https://www.uptodate.com/drug-interactions/?source=responsive_home#di-druglist
5. Diabetes Canada 2018. Clinical Practice Guidelines for the prevention and management of diabetes in Canada: Pharmacologic glycemic management of type 2 diabetes in adults: 2020. <https://guidelines.diabetes.ca/cpg/chapter-13-2020-update>
6. Apovian C et al. J Clin Endocrinol Metab 2015;100:342-62
7. Wharton S et al. Diabetes Metab Syndr Obes 2018;11:427-38
8. BC Cancer Agency. Tamoxifen Monograph. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Tamoxifen_monograph.pdf

Evidence pending

1. Tirzepatide. SURMOUNT-5. <https://clinicaltrials.gov/study/NCT05822830>
2. Tirzepatide. STOP KNEE-OA. <https://clinicaltrials.gov/study/NCT06191848>
3. Tirzepatide. SURMOUNT-MMO. <https://clinicaltrials.gov/study/NCT05556512>
4. Tirzepatide. SUMMIT. <https://clinicaltrials.gov/study/NCT04847557>
5. Semaglutide subcutaneous. STEP UP. <https://clinicaltrials.gov/study/NCT05646706>
6. Semaglutide oral. Novo Nordisk. OASIS clinical trial programme. <https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166110>
7. Semaglutide. STEP 9. <https://clinicaltrials.gov/study/NCT05064735>
8. Semaglutide subcutaneous. STEP HFpEF DM. <https://clinicaltrials.gov/study/NCT04916470>
9. Naltrexone-Bupropion. INFORMUS. <https://clinicaltrials.gov/study/NCT06098079>
10. US Food & Drug Administration. GLP1 agonists pulmonary aspiration. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
11. European Medicines Agency. GLP1 agonists pulmonary aspiration. Sep 2023. <https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-25-28-september-2023>
12. US Food & Drug Administration. GLP1 agonists alopecia. Jul-Sep 2023. <https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/july-september-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse>
13. Health Canada
 - Health Canada. GLP1 agonists suicide, self-harm, suicidal ideation. Nov 2023. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/new.html>
14. US Food & Drug Administration. GLP1 agonists suicidal thoughts actions. Jan 2024. <https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type>
15. European Medicines Agency. GLP1 agonists suicidal thoughts actions. Jul 2023. <https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists>

16. European Medicines Agency. Naltrexone-bupropion cardiovascular. Sep 2023. <https://www.ema.europa.eu/en/medicines/human/referrals/mysimba>
17. Semaglutide. FOCUS. <https://clinicaltrials.gov/study/NCT03811561>